Page 61 - Case Lab Case Analysis

There is not enough time to canvas executives below board level and even if you

could have it is questionable, given the severity of the situation, whether this would

have been undertaken.

The fifth action is within the remit of Blackthorn.

The last two actions are also within the purview of Blackthorn and it is he who will

call the shots.

Phissons plc.

Phissons is a large multinational agro-chemical company operating in over 100

countries. It was founded in the 1920s and had over the years diversified

extensively.

In mid 2016 it was six weeks from the launch of its major discovery of the last

decade a revolutionary asthma drug targeted primarily at the very young child

sufferer - Proxydychromil, when alarming news was conveyed to Blackthorn.

PROXYDYCHROMIL

Proxydychromil had been in development for over nine years and had cost in excess

of £250m to bring it to the market. It had passed all clinical trials in Europe and the

USA and was poised to be the company’s premier product.

Its value lay in that it not only alleviated the symptoms of asthma but it also helped

develop prolonged resistance to recurring episodes.